This is from the 4C: "The company made the strategic decision to continue with an intensive education program during the rollout of Cardiocel 3D. During the quarter, specially qualified Clinical Business Managers trained and supported 34 surgeons to facilitate its implementation..."
The fact they said it was a strategic decision means to me the 3D clinics is a significant business expense and the decision wasnt made lightly.
The new product suite is somewhat a double-edged sword - education and after sales support is required while sales ramp up slowly as products are adopted... so profit margins in the 3D business will ramp up over time....
Ann: Appendix 3B - Star Bright Placement Issue, page-36
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.68 |
Change
-0.320(2.67%) |
Mkt cap ! $246.9M | |||
| Open | High | Low | Value | Volume |
| $11.57 | $11.81 | $11.42 | $152.5K | 13.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 116 | $11.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.68 | 188 | 1 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |